Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Cardiologists should care abou...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR

Bibliographic Details
Main Authors: McMurray, J, Califf, R, Holman, R, Haffner, S, Lau, M, Pecher, E
Format: Conference item
Published: 2004
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
    by: Bethel, A, et al.
    Published: (2005)
  • Determining the most appropriate components for a composite clinical trial outcome.
    by: Bethel, M, et al.
    Published: (2008)
  • Parallel Evolution in <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content> over 39,000 Generations <italic toggle="yes">In Vivo</italic>
    by: Holly K. Huse, et al.
    Published: (2010-10-01)
  • Prediabetes and the risk of diabetes.
    by: McMurray, J, et al.
    Published: (2012)
  • Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
    by: Califf, R, et al.
    Published: (2008)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs